Residential and Outpatient Schizophrenia Patients' Sleep Health Differs.

Published Date: 27 Apr 2023

Residential and Outpatient Schizophrenia Patients' Sleep Health Varies.

Read Full News

Latest News

Delay Discounting Fails to Predict MDD Relapse, Q&A With Giles Story, PhD

Delay Discounting Fails to Predict MDD Relapse, Q&A With Giles Story, PhD

6 Psychiatry Headlines You Missed in January 2026

6 Psychiatry Headlines You Missed in January 2026

FDA Examines Generative AI in Psychiatry, With Hans Eriksson, MD, PhD Hans Eriksson, MD, PhD

As mental health AI tools rise, the FDA weighs benefits and risks, emphasizing oversight and performance testing. Eriksson discusses AI in psychiatric care.

Utilizing Alcohol Use Disorder Pharmacotherapy in Hepatology, With Hersh Shroff, MD, MPA Hersh Shroff, MD, MPA

Shroff emphasizes the need to address more than just liver health in patients with alcohol-associated liver disease and reviews trends in AUD pharmacotherapy prescriptions.

The Skin–Brain Axis: Emerging Evidence Transforming Dermatologic Care Lisa A. Swanson, MD, Enzo Berardesca, MD, Mohammad Jafferany, MD

Research reveals a significant skin-brain connection, linking inflammatory skin diseases to neurocognitive and emotional health, particularly in children with atopic dermatitis.

FDA Accepts NDA for Priority Review of Centanafadine to Treat Adult, Pediatric ADHD

FDA Accepts NDA for Priority Review of Centanafadine to Treat Adult, Pediatric ADHD

Todays Updates

Winter Sports and Lower Limb Motor Disability

People with lower limb motor disability need tailored equipment, training, and medical oversight to boost performance while preventing upper limb overload and skin problems.

Can Better Screening Prevent Maternal VTE Deaths?

Nearly half of maternal deaths from venous thromboembolism in France over 12 years were preventable.

'Concerning': CRC Continues to Shift Toward Younger Adults

Nearly half of new colorectal cancer cases now occur in people younger than age 65 years, highlighting the need for earlier screening and better symptom awareness.

Tight Glycemic Target in Gestational Diabetes Reduces Risks

Tight glycemic targets in gestational diabetes can lower the risk for large-for-gestational-age births without increasing the risk for serious maternal and neonatal complications.

Todays Updates

Winter Sports and Lower Limb Motor Disability

People with lower limb motor disability need tailored equipment, training, and medical oversight to boost performance while preventing upper limb overload and skin problems.

Can Better Screening Prevent Maternal VTE Deaths?

Nearly half of maternal deaths from venous thromboembolism in France over 12 years were preventable.

'Concerning': CRC Continues to Shift Toward Younger Adults

Nearly half of new colorectal cancer cases now occur in people younger than age 65 years, highlighting the need for earlier screening and better symptom awareness.

Tight Glycemic Target in Gestational Diabetes Reduces Risks

Tight glycemic targets in gestational diabetes can lower the risk for large-for-gestational-age births without increasing the risk for serious maternal and neonatal complications.

Latest News

Delay Discounting Fails to Predict MDD Relapse, Q&A With Giles Story, PhD

6 Psychiatry Headlines You Missed in January 2026

As mental health AI tools rise, the FDA weighs benefits and risks, emphasizing oversight and performance testing. Eriksson discusses AI in psychiatric care.

Shroff emphasizes the need to address more than just liver health in patients with alcohol-associated liver disease and reviews trends in AUD pharmacotherapy prescriptions.

Research reveals a significant skin-brain connection, linking inflammatory skin diseases to neurocognitive and emotional health, particularly in children with atopic dermatitis.

FDA Accepts NDA for Priority Review of Centanafadine to Treat Adult, Pediatric ADHD

News All Time

Psychiatry in 2025: Year in Review

Psychiatry in 2025: Year in Review

Teva Pharmaceuticals Submits NDA on TEV-‘749 for Schizophrenia to the FDA

Teva Pharmaceuticals Submits NDA on TEV-‘749 for Schizophrenia to the FDA

Adjunctive Lumateperone Significantly Improves MDD Symptoms by Day 43

Adjunctive Lumateperone Significantly Improves MDD Symptoms by Day 43

4 Psychiatry Headlines You Missed in November 2025

4 Psychiatry Headlines You Missed in November 2025

Mental Health Apps Gain High Uptake but Struggle With Adherence, Retention

Mental Health Apps Gain High Uptake but Struggle With Adherence, Retention

Otsuka Pharmaceuticals Submits NDA for Centanafadine to Treat ADHD in Children

Otsuka Pharmaceuticals Submits NDA for Centanafadine to Treat ADHD in Children

Adjunctive Perospirone Safe, Well-Tolerated for MDD in Phase 4 Trial

Adjunctive Perospirone Safe, Well-Tolerated for MDD in Phase 4 Trial

FDA Clears BrainsWay’s TMS Device for Adolescents with MDD Aged 15 to 21 Years

FDA Clears BrainsWay’s TMS Device for Adolescents with MDD Aged 15 to 21 Years

Single Dose of MM120 (LSD) Shows Lasting Anxiety Reduction in GAD: Phase 2b Results Chelsie Derman

A phase 2b trial finds a single 100 μg dose of MM120 reduced GAD symptoms with benefits lasting 12 weeks, highlighting the promise of psychedelic therapy.

FDA Releases CRL Detailing Safety Concerns for MDMA-Assisted Therapy in PTSD Chelsie Derman

MDMA’s CRL, now available to the public, cites gaps in safety data, selection bias, and limited durability.

Prenatal Opioid Pain Medications Likely Not Linked to Autism or ADHD Risk Chelsie Derman

A study suggests associations between opioids during pregnancy and neurodevelopmental disorders are mainly due to confounding factors, not causal effects.

Atopic Eczema Linked to Suicidal Ideation in Global Study of 30,000 Adults Chelsie Derman

EADV 2025 findings show patients with atopic eczema face greater risks of depression, anxiety, sleep disorders, and stigmatization.

FDA Initiates Acetaminophen Label Change, Leucovorin Approval for Cerebral Folate Deficiency Abigail Brooks, MA

The Agency initiated an acetaminophen label change to reflect evidence of potential harms in pregnant women and an approval of leucovorin for CFD.

Daily Ammoxetine at 40, 60 mg Outperforms Placebo for MDD in Phase 2 Trial Chelsie Derman

A phase 2 trial demonstrated the effectiveness, safety, and tolerability of ammoxetine (40 and 60 mg) in patients with major depressive disorder.

APhA, Coalition of Autism Scientists Cite Insufficient Data to Support Acetaminophen, Autism Link Abigail Brooks, MA

Both organizations defend the use of Tylenol during pregnancy, citing “rigorous” and “reputable” research suggesting it does not cause autism in children.

5 Psychiatry Headlines You Missed in September 2025 Chelsie Derman

This month in review focuses on innovative therapies in psychiatry, including MM120 for anxiety and ammoxetine for depression, as well as providing safety insights.

Recommended News For You

Achieves a High Disease Control Rate in Head and Neck BCC with Vismodegib-RT Regimen.

Ketamine plus psychotherapy for "excellent" PTSD

Coffee, Tea Tied to Lower Risk of Head and Neck Cancer

Medical Journal March 29, 2023

3D virtual staining technology enables non-invasive observation of cancer tissue

After three years, responses to mounetuzumab in follicular lymphoma are still stable.

Results for Prostate Cancer Are Associated With PSA Nadir 6 Months After Primary RT.

Recommended Articles For You

Next-Gen CAR Cell Therapies in Oncology: Frontiers in Solid Tumors & Hematologic Malignancies 

Skin-Sparing Mastectomy: Balancing Cancer Control with Cosmetic Results 

Cowden Syndrome and Cancer: Understanding the Risk Factors  

HPV-Related Cervical Cancer: Advances in Screening, Preventiofn & Treatment 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Avoiding Neuropathy From Chemo; Predictive Value of Screening EKGs

2.

PNH With Extravascular Hemolysis Approves Factor D Inhibitor.

3.

Study reveals link between new-onset type 2 diabetes and some obesity-related cancers

4.

Extended lymphadenectomy has no survival benefit in patients with muscle-invasive bladder cancer.

5.

Don't Call It Cancer; Clues to 'Exceptional' Responses; More Predictions for 2025

1.

Getting to Know RDW and SD: How They Relate to Anemia, Inflammation, and More 

2.

Advancements in Survival Mechanisms and Prognostic Determinants in Acute Myeloid Leukemia

3.

Case Study: Advancing Preclinical Oncology Drug Development with Quantitative Systems Pharmacology

4.

The Converging Frontiers of Radiation Oncology and Systemic Therapies by 2025

5.

Uncovering the Hidden Gallons: How Much Blood Is Inside the Human Body?

1.

International Lung Cancer Congress®

2.

Future NRG Oncology Meeting

3.

Genito-Urinary Oncology Summit 2026

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Deep Dive Into EGFR Mutation Positive Non-Small Cell Lung Cancer

2.

Navigating the Complexities of Ph Negative ALL - Part VI

3.

Exploring Best Possible Treatment Strategies in Advanced Urothelial Carcinoma- A Panel Discussion

4.

Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part IV

5.

Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part III

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot